Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection

Liang Shan, Robert F. Siliciano

*J Clin Invest.* 2014;124(6):2368-2371. [https://doi.org/10.1172/JCI75799](https://doi.org/10.1172/JCI75799).

**Commentary**

Chronic immune activation is a key factor in HIV-1 disease progression. The translocation of microbial products from the intestinal lumen into the systemic circulation occurs during HIV-1 infection and is associated closely with immune activation; however, it has not been determined conclusively whether microbial translocation drives immune activation or occurs as a consequence of HIV-1 infection. In an important study in this issue of the *JCI*, Kristoff and colleagues describe the role of microbial translocation in producing immune activation in an animal model of HIV-1 infection, SIV infection of pigtailed macaques. Blocking translocation of intestinal bacterial LPS into the circulation dramatically reduced T cell activation and proliferation, production of proinflammatory cytokines, and plasma SIV RNA levels. This study directly demonstrates that microbial translocation promotes the systemic immune activation associated with HIV-1/SIV infection.

Find the latest version:

[https://jci.me/75799/pdf](https://jci.me/75799/pdf)
Chronic immune activation is a key factor in HIV-1 disease progression. The translocation of microbial products from the intestinal lumen into the systemic circulation occurs during HIV-1 infection and is associated closely with immune activation; however, it has not been determined conclusively whether microbial translocation drives immune activation or occurs as a consequence of HIV-1 infection. In an important study in this issue of the JCI, Kristoff and colleagues describe the role of microbial translocation in producing immune activation in an animal model of HIV-1 infection, SIV infection of pigtailed macaques. Blocking translocation of intestinal bacterial LPS into the circulation dramatically reduced T cell activation and proliferation, production of proinflammatory cytokines, and plasma SIV RNA levels. This study directly demonstrates that microbial translocation promotes the systemic immune activation associated with HIV-1/SIV infection.

Immune activation and disease progression in HIV-1 infection

In humans, the gut-associated lymphoid tissue (GALT) contains a large number of activated CD4+CCR5+ T cells, thus serving as a major site of viral replication and CD4+ T cell depletion early in the course of HIV-1 infection (1, 2). In contrast to the rapid depletion of intestinal CD4+ T cells, the decline of CD4+ T cells in peripheral blood is much slower and less extensive during acute HIV-1 infection, suggesting that the majority of peripheral CD4+ T cells are nonpermissive at this stage (2, 3). During the chronic phase of infection, systemic immune activation is very strongly correlated with disease progression (4). Activation of CD4+ T cells increases co-receptor expression and renders these cells more susceptible to HIV-1 infection, and these cycles of activation and infection may drive progression of disease to AIDS (5). In contrast, SIV infection in natural host species very rarely progresses to AIDS and does not result in increased levels of immune activation, despite high levels of virus replication (6, 7). Infection and depletion of CD4+ T cells in GALT can be observed in both SIV and HIV-1 infection; however, natural host species infected with SIV do not often develop systemic immune activation, despite loss of GALT CD4+ T cells (6, 7), suggesting that factors other than direct infection and mucosal CD4+ T cell loss are essential for the increased degree of immune activation seen in HIV-1 infection.

Microbial translocation in HIV-1 infection

Translocation of microbial products from the lumen of the gastrointestinal tract into the circulation often occurs in HIV-1–infected individuals and is closely associated with systemic immune activation. Many studies have shown that HIV-1–infected individuals have elevated plasma levels of LPS and soluble CD14, which is indicative of LPS-induced monocyte and macrophage activation (8). Plasma levels of other microbial products, such as bacterial DNA and flagellin, are also increased in HIV-1–infected individuals compared with healthy controls (8, 9). Furthermore, there is a negative correlation between plasma
Figure 1
Microbial translocation and immune activation during HIV-1 infection. (A) The intact intestinal epithelium in uninfected individuals. Commensal bacteria and released microbial products, including LPS, are restricted to the gut lumen by a continuous lining of enterocytes. (B) Translocation of commensal bacteria and bacterial products from the gut lumen into the intestinal wall and peripheral blood during HIV-1 infection. HIV-1 infection induces death of intestinal epithelial cells and depletes intestinal CD4+ T cells, particularly Th17 cells. Loss of intestinal epithelial cells allows commensal bacteria to enter intestinal wall. Loss of Th17 cells allows bacterial overgrowth. Translocation of microbial products into peripheral blood causes systemic immune activation. Activated peripheral CD4+ T cells are highly susceptible to HIV-1 infection. (C) The drug sevelamer blocks translocation of bacterial LPS into the systemic circulation, preventing immune activation. Sevelamer binds and sequesters bacterial LPS in intestinal lumen. Blocking bacterial LPS translocation of LPS into the circulation prevents systemic immune activation, leaving the majority of peripheral CD4+ T cells quiescent and unsusceptible to HIV-1 infection.
Microbial translocation is indispensable for HIV-1–associated systemic immune activation

Experiments to directly evaluate the contribution of microbial translocation in the pathogenesis of HIV-1 infection require blocking the interaction between microbial products and host immune cells without directly affecting viral replication. In this issue, Kristoff and colleagues used Th17 cells, which produce cytokines, including IL-17 and IL-22, to recruit and activate neutrophils as well as promote the release of antimicrobial peptides (12). Th17 cells are preferentially depleted by direct infection, likely due to the high expression of the CCR5 coreceptor on these cells (13). As a consequence of viral infection, damage to intestinal epithelial barrier and decreased control of intestinal bacteria result in the translocation of commensal microbial products, including LPS, into circulation. In principle, these products can induce production of proinflammatory cytokines and promote peripheral T cell activation and cycling (Figure 1). Microbial translocation occurs during HIV-1 and pathogenic SIV infection but not during SIV infection of natural host species (5), suggesting that microbial translocation may play a role in viral infection and disease progression. Interestingly, intravenous LPS administration in natural host species infected with SIV does induce systemic immune activation, increase SIV replication, and accelerate CD4+ T cell depletion (14). Nevertheless, it is unclear whether and to what degree microbial translocation drives immune activation and disease progression or if the breach of epithelial barrier function occurs concomitantly with immune activation as a consequence of viral infection.

Microbial translocation may be important for complete reconstitution of gastrointestinal immunity. Kristoff and colleagues demonstrate that sevelamer can effectively block LPS translocation in SIV-infected PTMs and alleviate systemic immune activation during acute infection. It will be important to further investigate the effects of sevelamer on mucosal immune reconstitution in chronically infected PTMs. Because sevelamer is approved to treat hyperphosphatemia in patients with chronic kidney disease, it may be reasonable to assess whether sevelamer can attenuate immune activation and promote restoration of mucosal immunity in some cART-treated patients, especially immunological nonresponders, who maintain high levels of microbial translocation and immune activation and fail to restore CD4+ T cell population despite long-term cART (9, 21).

Acknowledgments

This work was supported by NIH grant T32 AI07019 (to L. Shan), the Martin Delaney Collaboratory of AIDS Researchers for Eradication and the Delaney AIDS Research Enterprise (NIH grants AI096113 and AI096109 to R.F. Siliciano), the Foundation for AIDS Research grant 108165-50-RGRL (to R.F. Siliciano), NIH grant 43222 (to R.F. Siliciano), and the Howard Hughes Medical Institute (to R.F. Siliciano).

Address correspondence to: Robert F. Siliciano, Johns Hopkins University School of Medicine, 733 North Broadway, BRB 879, Baltimore, Maryland 21205, USA. Phone: 410.955.2958; Fax: 410.955.0964; E-mail: rsiliciano@jhmi.edu.

2. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all
Targeting secondary immune responses to cetuximab: CD137 and the outside story

Julie E. Bauman1 and Jennifer R. Grandis2

1Department of Internal Medicine (Hematology/Oncology) and 2Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Cetuximab is a murine-human chimeric IgG1 mAb directed against the EGFR that is approved for use in patients with colorectal and head and neck carcinomas. While some patients benefit greatly from cetuximab, many do not; therefore, strategies to increase the efficacy of this drug are of great clinical interest. In this issue of the JCI, Kohrt and colleagues report a strategy for enhancing the secondary immune response to cetuximab that involves sequential targeting with an agonist mAb against CD137 expressed on NK and T cells.

The inside story on cetuximab

EGFR, also known as HER1, is a member of the erythroblastic leukemia viral oncoregion homolog (ERBB) family of transmembrane receptor tyrosine kinases (RTK). Deregulation of EGFR signaling initiates aberrant growth, proliferation, and angiogenesis. The clinical development of mAbs targeting the extracellular ligand-binding domain and small molecules targeting the intracellular ATPase domain of EGFR was originally compelled by the association of EGFR overexpression with poor prognosis in multiple epithelial malignancies. Despite overexpression of EGFR in the vast majority of human aerodigestive cancers, cetuximab has only gained FDA approval for use in patients with head and neck squamous cell carcinoma (HNSCC) and WT KRAS colorectal cancer (CRC), with monotherapeutic activity observed in just 10% to 20% of patients. Clinical selection for cetuximab is confounded by the absence of a reliable biomarker to predict patient response. Mutations that result in constitutively activated EGFR are associated with patient responsiveness to small-molecule EGFR inhibitors in lung cancer; however, these mutations are rarely identified in HNSCC or CRC. Moreover, neither EGFR overexpression nor EGFR amplification predicts clinical benefit from cetuximab (1, 2). The discordance between EGFR target expression and the efficacy of target blockade by cetuximab has broadened investigation into the mechanisms of action and development of therapeutic resistance.

Initial strategies to enhance cetuximab activity have focused on the intracellular signaling hypothesis (Figure 1A), which suggests that de novo or compensatory activation of parallel RTKs (alternate HER family members, cMet, IGF1R, FGFR, VEGFR), downstream EGFR-signaling nodes (RAS, PI3K, STAT3, SRC), or cell cycle promoters (aurora kinase, CDK4/6) circumvent EGFR blockade in HNSCC preclinical models; therefore, coinhibition of these resistance nodes should enhance the activity of cetuximab (3). Cetuximab resistance has also been attributed to heterodimerization of EGFR with other HER proteins that potentially prevent recognition of EGFR by cetuximab as well as acquisition of gain-of-function PIK3CA mutations that activate signaling downstream of EGFR. In CRC patients, activating KRAS and BRAF mutations confer clinical cetuximab resistance. Progressive insight into the complexity and plasticity of the EGFR signaling network has propelled cetuximab-combination trials to evaluate the efficacy of cotargeting these purported resistance nodes (Table 1).

Conflict of interest: Jennifer Grandis receives laboratory research funding from Novartis.

Citation for this article: J Clin Invest. 2014;124(6):2371-2375. doi:10.1172/JCI76264.